{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Botox%C2%AE+injection", "query": { "intervention": "Botox® injection" }, "page_size": 10 }, "pagination": { "page": 1, "page_size": 10, "total_count": 117, "total_pages": 12, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Botox%C2%AE+injection&page=2&page_size=10", "previous_page_url": null }, "source": "remote", "last_synced_at": "2026-09-04T10:54:20.289Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT02191579", "title": "Efficacy and Safety Study of BOTOX® Compared to Topiramate for the Prevention of Chronic Migraine in Adults", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE4" ], "conditions": [ "Migraine Disorders" ], "interventions": [ { "name": "onabotulinumtoxinA", "type": "BIOLOGICAL" }, { "name": "Topiramate", "type": "DRUG" } ], "intervention_types": [ "BIOLOGICAL", "DRUG" ], "sponsor": "Allergan", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "65 Years", "sex": "ALL", "summary": "18 Years to 65 Years" }, "enrollment_count": 282, "start_date": "2014-08-05", "completion_date": "2017-09-01", "has_results": true, "last_update_posted_date": "2018-06-07", "last_synced_at": "2026-09-04T10:54:20.289Z", "location_count": 32, "location_summary": "Phoenix, Arizona • Encinitas, California • Fresno, California + 28 more", "locations": [ { "city": "Phoenix", "state": "Arizona" }, { "city": "Encinitas", "state": "California" }, { "city": "Fresno", "state": "California" }, { "city": "Newport Beach", "state": "California" }, { "city": "Denver", "state": "Colorado" } ], "official_url": "https://clinicaltrials.gov/study/NCT02191579" }, { "nct_id": "NCT01249417", "title": "Dysport® Pediatric Lower Limb Spasticity Study", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Cerebral Palsy", "Muscle Spasticity", "Children" ], "interventions": [ { "name": "Botulinum toxin type A", "type": "BIOLOGICAL" }, { "name": "Placebo", "type": "DRUG" } ], "intervention_types": [ "BIOLOGICAL", "DRUG" ], "sponsor": "Ipsen", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "2 Years", "maximum_age": "17 Years", "sex": "ALL", "summary": "2 Years to 17 Years" }, "enrollment_count": 241, "start_date": "2011-07", "completion_date": "2014-06", "has_results": true, "last_update_posted_date": "2022-09-28", "last_synced_at": "2026-09-04T10:54:20.289Z", "location_count": 8, "location_summary": "Aurora, Colorado • Chicago, Illinois • New Orleans, Louisiana + 5 more", "locations": [ { "city": "Aurora", "state": "Colorado" }, { "city": "Chicago", "state": "Illinois" }, { "city": "New Orleans", "state": "Louisiana" }, { "city": "Detroit", "state": "Michigan" }, { "city": "Saint Paul", "state": "Minnesota" } ], "official_url": "https://clinicaltrials.gov/study/NCT01249417" }, { "nct_id": "NCT01600716", "title": "Safety and Efficacy Study of OnabotulinumtoxinA for the Treatment of Urinary Incontinence Due to Neurogenic Detrusor Overactivity (NDO) in Non-Catheterizing Patients With Multiple Sclerosis (MS)", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Urinary Incontinence", "Multiple Sclerosis", "Neurogenic Bladder" ], "interventions": [ { "name": "OnabotulinumtoxinA", "type": "BIOLOGICAL" }, { "name": "Placebo (Normal Saline)", "type": "DRUG" } ], "intervention_types": [ "BIOLOGICAL", "DRUG" ], "sponsor": "Allergan", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 144, "start_date": "2012-06-13", "completion_date": "2015-03-27", "has_results": true, "last_update_posted_date": "2019-04-30", "last_synced_at": "2026-09-04T10:54:20.289Z", "location_count": 1, "location_summary": "Mountlake Terrace, Washington", "locations": [ { "city": "Mountlake Terrace", "state": "Washington" } ], "official_url": "https://clinicaltrials.gov/study/NCT01600716" }, { "nct_id": "NCT04815967", "title": "Efficacy and Safety Study of MYOBLOC® in the Treatment of Adult Upper Limb Spasticity", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2", "PHASE3" ], "conditions": [ "Spasticity", "Cerebrovascular Accident", "Multiple Sclerosis", "Traumatic Brain Injury", "Cervical Spinal Cord Injury", "Cerebral Palsy" ], "interventions": [ { "name": "Phase 2; Low Dose MYOBLOC (10,000 Units)", "type": "DRUG" }, { "name": "Phase 2; High Dose MYOBLOC (20,000 Units)", "type": "DRUG" }, { "name": "Phase 2; Placebo", "type": "DRUG" }, { "name": "Phase 3; MYOBLOC", "type": "DRUG" }, { "name": "Phase 3; Placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Solstice Neurosciences, LLC, a subsidiary of MDD US Operations, LLC", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "80 Years", "sex": "ALL", "summary": "18 Years to 80 Years" }, "enrollment_count": 32, "start_date": "2021-11-02", "completion_date": "2023-04-23", "has_results": true, "last_update_posted_date": "2026-05-27", "last_synced_at": "2026-09-04T10:54:20.289Z", "location_count": 4, "location_summary": "Downey, California • Boise, Idaho • Port Royal, South Carolina + 1 more", "locations": [ { "city": "Downey", "state": "California" }, { "city": "Boise", "state": "Idaho" }, { "city": "Port Royal", "state": "South Carolina" }, { "city": "Dallas", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT04815967" }, { "nct_id": "NCT00234507", "title": "Study of a Single Administration of 3 Doses of Dysport® for the Treatment of Benign Essential Blepharospasm", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Blepharospasm" ], "interventions": [ { "name": "Botulinum toxin type A", "type": "BIOLOGICAL" } ], "intervention_types": [ "BIOLOGICAL" ], "sponsor": "Ipsen", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 120, "start_date": "2003-01", "completion_date": "2004-05-25", "has_results": false, "last_update_posted_date": "2019-07-29", "last_synced_at": "2026-09-04T10:54:20.289Z", "location_count": 14, "location_summary": "Phoenix, Arizona • Fountain Valley, California • Los Angeles, California + 10 more", "locations": [ { "city": "Phoenix", "state": "Arizona" }, { "city": "Phoenix", "state": "Arizona" }, { "city": "Fountain Valley", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "Gainesville", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT00234507" }, { "nct_id": "NCT06212661", "title": "Migraine Medication Effects on Urinary Symptoms", "overall_status": "ENROLLING_BY_INVITATION", "study_type": "OBSERVATIONAL", "phases": [], "conditions": [ "Overactive Bladder", "Bladder Pain Syndrome", "Migraine Disorders", "Overactive Bladder Syndrome", "Overactive Detrusor", "Migraine", "Interstitial Cystitis" ], "interventions": [ { "name": "Ubrogepant", "type": "DRUG" }, { "name": "Rimegepant", "type": "DRUG" }, { "name": "Atogepant", "type": "DRUG" }, { "name": "Eptinezumab", "type": "DRUG" }, { "name": "Fremanezumab", "type": "DRUG" }, { "name": "Galcanezumab", "type": "DRUG" }, { "name": "Erenumab", "type": "DRUG" }, { "name": "Botulinum toxin A", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "The Cleveland Clinic", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "FEMALE", "summary": "18 Years and older · Female only" }, "enrollment_count": 200, "start_date": "2024-04-05", "completion_date": "2026-12", "has_results": false, "last_update_posted_date": "2025-10-01", "last_synced_at": "2026-09-04T10:54:20.289Z", "location_count": 1, "location_summary": "Cleveland, Ohio", "locations": [ { "city": "Cleveland", "state": "Ohio" } ], "official_url": "https://clinicaltrials.gov/study/NCT06212661" }, { "nct_id": "NCT00156910", "title": "A Study Using Botulinum Toxin Type A as Headache Prophylaxis for Migraine Patients With Frequent Headaches", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Migraine Disorders" ], "interventions": [ { "name": "Botulinum Toxin Type A", "type": "BIOLOGICAL" }, { "name": "Placebo (saline)", "type": "OTHER" } ], "intervention_types": [ "BIOLOGICAL", "OTHER" ], "sponsor": "Allergan", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "65 Years", "sex": "ALL", "summary": "18 Years to 65 Years" }, "enrollment_count": 679, "start_date": "2006-02", "completion_date": "2008-07", "has_results": true, "last_update_posted_date": "2013-11-18", "last_synced_at": "2026-09-04T10:54:20.289Z", "location_count": 1, "location_summary": "Seattle, Washington", "locations": [ { "city": "Seattle", "state": "Washington" } ], "official_url": "https://clinicaltrials.gov/study/NCT00156910" }, { "nct_id": "NCT00752050", "title": "Safety and Efficacy Study of Repeat Treatment With PurTox® Botulinum Toxin Type A for Frown Lines Between the Eyebrows", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Glabellar Rhytides", "Frown Lines Between the Eyebrows" ], "interventions": [ { "name": "Mentor Purified Toxin Botulinum Toxin Type A", "type": "DRUG" }, { "name": "Preservative-free Saline", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Mentor Worldwide, LLC", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 699, "start_date": "2007-11", "completion_date": "2009-03", "has_results": false, "last_update_posted_date": "2011-09-12", "last_synced_at": "2026-09-04T10:54:20.289Z", "location_count": 1, "location_summary": "Santa Barbara, California", "locations": [ { "city": "Santa Barbara", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT00752050" }, { "nct_id": "NCT04124939", "title": "Is 10 Injections of Bladder Botox Less Painful Than 20 Injections?", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE4" ], "conditions": [ "Overactive Bladder" ], "interventions": [ { "name": "OnabotulinumtoxinA 100 Units", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Wake Forest University Health Sciences", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "90 Years", "sex": "FEMALE", "summary": "18 Years to 90 Years · Female only" }, "enrollment_count": 41, "start_date": "2019-11-10", "completion_date": "2023-02-23", "has_results": true, "last_update_posted_date": "2024-04-17", "last_synced_at": "2026-09-04T10:54:20.289Z", "location_count": 2, "location_summary": "Greensboro, North Carolina • Winston-Salem, North Carolina", "locations": [ { "city": "Greensboro", "state": "North Carolina" }, { "city": "Winston-Salem", "state": "North Carolina" } ], "official_url": "https://clinicaltrials.gov/study/NCT04124939" }, { "nct_id": "NCT02002884", "title": "Dose-response Study of Efficacy and Safety of Botulinum Toxin Type A to Treat Spasticity of the Arm(s) or of Arm(s) and Leg(s) in Cerebral Palsy", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Cerebral Palsy", "Spasticity" ], "interventions": [ { "name": "IncobotulinumtoxinA (8 Units per kg body weight)", "type": "DRUG" }, { "name": "IncobotulinumtoxinA (6 Units per kg body weight)", "type": "DRUG" }, { "name": "IncobotulinumtoxinA (2 Units per kg body weight)", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Merz Pharmaceuticals GmbH", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "2 Years", "maximum_age": "17 Years", "sex": "ALL", "summary": "2 Years to 17 Years" }, "enrollment_count": 351, "start_date": "2014-03-28", "completion_date": "2018-08-28", "has_results": true, "last_update_posted_date": "2021-08-05", "last_synced_at": "2026-09-04T10:54:20.289Z", "location_count": 6, "location_summary": "Gulf Breeze, Florida • Loxahatchee Groves, Florida • Savannah, Georgia + 3 more", "locations": [ { "city": "Gulf Breeze", "state": "Florida" }, { "city": "Loxahatchee Groves", "state": "Florida" }, { "city": "Savannah", "state": "Georgia" }, { "city": "Chicago", "state": "Illinois" }, { "city": "Royal Oak", "state": "Michigan" } ], "official_url": "https://clinicaltrials.gov/study/NCT02002884" } ] }